HeyJaredOpen Forum Infect Dis
- Indexed articles, last 90 days
- 16
- Latest publication
- Sep 4, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 28, 2026
Latest articles
Recombinant Flu Vaccine Cuts Nursing Home Outbreaks (opens the original)
Read excerpt
Nursing homes using recombinant quadrivalent influenza vaccine (RIV4) experienced 18% fewer laboratory-confirmed influenza outbreaks compared with facilities using standard-dose egg-based inactivated quadrivalent influenza vaccine (IIV4) during the 2019-2020 season in a cluster-randomized trial. However, no differences in outbreak rates were seen between vaccine groups during the 2020-2021 season, when influenza circulation was historically low. "These findings suggest that enhanced influenza va
Early Oseltamivir Tied to Lower Hospitalization Risk in Flu (opens the original)
Read excerpt
Oseltamivir treatment within 6 hours of a positive influenza test was associated with reduced risk for hospitalization among outpatient veterans. "[The study] results show meaningful reductions in hospitalization and ICU admission risk in this patient population and support the benefits of oseltamivir in the outpatient setting," the authors wrote. The study was led by Lei Yan, Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center, Veterans Affairs Connecticut Health
Pneumonia Gaps Persist After PCV13 Rollout (opens the original)
Read excerpt
Inpatient all-cause pneumonia rates among US adults decreased following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in children. However, significant disparities persisted during 2017-2019, with Black adults, those with at-risk or high-risk conditions, and individuals with annual household income (HHI) below $100,000 experiencing disproportionately higher rates of hospitalized pneumonia. “Despite the reduction in cases, though, disparities in the burden of disease re
Fostemsavir Shows Promise in Multidrug-Resistant HIV (opens the original)
Read excerpt
In heavily treatment-experienced people with multidrug-resistant HIV-1 in France, fostemsavir-based antiretroviral therapy maintained viral suppression in 91% of those already suppressed and achieved suppression in 63% of those with detectable virus, while ibalizumab-based regimens achieved suppression in 36%. "People who are HTE [heavily treatment-experienced] and virologically suppressed maintain virologic control after 2 years to switching to an FTR-based regimen, which represents a valuable
Dolutegravir-Lamivudine Sustains HIV Suppression (opens the original)
Read excerpt
In a 3-year French real-world study, dolutegravir-lamivudine achieved high rates of viral suppression in treatment-naive and pretreated people living with HIV, with few virologic failures and a favorable safety profile. "This large real-world observational study demonstrated high virological success for up to 3 years on dolutegravir/lamivudine…with a favorable safety profile. Body weight remained generally stable, indicating no significant impact of dolutegravir/lamivudine," the authors wrote. "
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.